Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
59.7M
-
Number of holders
-
61
-
Total 13F shares, excl. options
-
39.1M
-
Shares change
-
-16.3K
-
Total reported value, excl. options
-
$534M
-
Value change
-
-$2.18M
-
Number of buys
-
28
-
Number of sells
-
-29
-
Price
-
$13.66
Significant Holders of Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) as of Q3 2023
69 filings reported holding ELVN - Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q3 2023.
Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) has 61 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39.1M shares
of 59.7M outstanding shares and own 65.4% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (9M shares), 5AM Venture Management, LLC (5.16M shares), FMR LLC (3.68M shares), VR Adviser, LLC (2.95M shares), COMMODORE CAPITAL LP (2.9M shares), CITADEL ADVISORS LLC (2.35M shares), Fairmount Funds Management LLC (2.13M shares), RA CAPITAL MANAGEMENT, L.P. (2.12M shares), BlackRock Inc. (1.57M shares), and Cormorant Asset Management, LP (1.22M shares).
This table shows the top 61 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.